Trial · NCT00101816
Results by group125
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 125
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Major and Overall Hematologic Response (MaHR and OHR) | Imatinib-intolerant | MaHR | 2 | Participants | |
| Major and Overall Hematologic Response (MaHR and OHR) | Imatinib-resistant | MaHR | 34 | Participants | |
| Major and Overall Hematologic Response (MaHR and OHR) | Total | MaHR | 36 | Participants | |
| Major and Overall Hematologic Response (MaHR and OHR) | Imatinib-intolerant | OHR | 4 | Participants | |
| Major and Overall Hematologic Response (MaHR and OHR) | Imatinib-resistant | OHR | 50 | Participants | |
| Major and Overall Hematologic Response (MaHR and OHR) | Total | OHR | 54 | Participants | |
| Median Duration of Major Hematologic Response (MaHR) | Participants Acheiving MaHR | 22.4 | Full Range 1.6 to 27.3 | months | |
| Median Duration of Overall Hematologic Response (OHR) | Participants Acheiving OHR | 14.7 | 95% Confidence Interval 10.0 to 22.6 | months | |
| Time to MaHR and OHR | Participants Acheiving MaHR | 63.5 | 95% Confidence Interval 40.0 to 85.0 | days | |
| Time to MaHR and OHR | Participants Acheiving OHR | 30.0 | 95% Confidence Interval 29.0 to 37.0 | days | |
| Number of Participants With Complete, Partial, Minor, Minimal, or No Cytogenetic Response | Imatinib-intolerant | Complete (0% Ph+ metaphases) | 2 | Participants | |
| Number of Participants With Complete, Partial, Minor, Minimal, or No Cytogenetic Response | Imatinib-resistant | Complete (0% Ph+ metaphases) | 27 | Participants | |
| Number of Participants With Complete, Partial, Minor, Minimal, or No Cytogenetic Response | Total | Complete (0% Ph+ metaphases) | 29 | Participants | |
| Number of Participants With Complete, Partial, Minor, Minimal, or No Cytogenetic Response | Imatinib-intolerant | Partial (>0% to 35% Ph+ metaphases) | 0 | Participants | |
| Number of Participants With Complete, Partial, Minor, Minimal, or No Cytogenetic Response | Imatinib-resistant | Partial (>0% to 35% Ph+ metaphases) | 8 | Participants | |
| Number of Participants With Complete, Partial, Minor, Minimal, or No Cytogenetic Response | Total | Partial (>0% to 35% Ph+ metaphases) | 8 | Participants | |
| Number of Participants With Complete, Partial, Minor, Minimal, or No Cytogenetic Response | Imatinib-intolerant | Minor (>35% to 65% Ph+ metaphases) | 0 | Participants | |
| Number of Participants With Complete, Partial, Minor, Minimal, or No Cytogenetic Response | Imatinib-resistant | Minor (>35% to 65% Ph+ metaphases) | 3 | Participants | |
| Number of Participants With Complete, Partial, Minor, Minimal, or No Cytogenetic Response | Total | Minor (>35% to 65% Ph+ metaphases) | 3 | Participants | |
| Number of Participants With Complete, Partial, Minor, Minimal, or No Cytogenetic Response | Imatinib-intolerant | Minimal (>65% to 95% Ph+ metaphases) | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00101816/results